AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Calamos Wealth Management LLC

Calamos Wealth Management LLC lessened its stake in AstraZeneca PLC (NASDAQ:AZNFree Report) by 24.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,273 shares of the company’s stock after selling 5,851 shares during the period. Calamos Wealth Management LLC’s holdings in AstraZeneca were worth $1,231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Fairfield Bush & CO. acquired a new position in AstraZeneca in the second quarter valued at $25,000. Anchor Investment Management LLC acquired a new position in AstraZeneca in the fourth quarter valued at $26,000. ICA Group Wealth Management LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $26,000. Parkside Financial Bank & Trust boosted its stake in shares of AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after buying an additional 390 shares during the period. Finally, Compagnie Lombard Odier SCmA acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $27,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Morgan Stanley started coverage on shares of AstraZeneca in a research note on Tuesday, January 23rd. They set an “overweight” rating for the company. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus target price of $80.00.

Get Our Latest Analysis on AstraZeneca

AstraZeneca Trading Up 0.3 %

NASDAQ AZN opened at $68.55 on Friday. The stock has a market capitalization of $212.53 billion, a P/E ratio of 35.70, a P/E/G ratio of 1.26 and a beta of 0.50. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $76.56. The firm has a 50-day moving average price of $66.24 and a 200 day moving average price of $65.88. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.57.

AstraZeneca (NASDAQ:AZNGet Free Report) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by ($0.01). The firm had revenue of $12.02 billion for the quarter, compared to analysts’ expectations of $12.07 billion. AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.69 earnings per share. Equities research analysts expect that AstraZeneca PLC will post 4 EPS for the current year.

AstraZeneca Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Investors of record on Friday, February 23rd were issued a dividend of $0.965 per share. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a yield of 2.3%. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s dividend payout ratio is currently 100.52%.

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.